Name: MarketsandMarkets Real-World Evidence and Market Access Conference - EU Edition
Start: 2023-10-05
End: 2023-10-06
Location: The Westin Grand Frankfurt, Germany

WHAT TO EXPECT

Regulatory view around data quality & data standards.
Leveraging RWE for improving market access.
The adoption & role of AI & ML in clinical trials.
Real-world evidence & Digital Health - The expanded role of RWE for digital health.
Real-World Data & Advanced Analytics.
RWE to inform decision making process in rare diseases where there is lack of evidence.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From Pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence
Real-World Data
Data Analytics
Health Economics & Outcomes Research- HEOR
Market Access/Value Access
Policy
Clinical Development & research
Clinical trial
Centre for Observational and Real-World Evidence
Epidemiology
Oncology-RWE
Pricing and Reimbursement
Medical Affairs
Pharmacovigilance
Life Science Analytics
Big data
Data Science
Bio-Statistics
Consumer Healthcare

CONFERENCE AGENDA

Registration	08:15 - 09:00
Welcome note by MarketsandMarkets	09:00 - 09:05
Opening remarks by the Chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB	09:05 - 09:10
Application of Real-World Evidence (RWE) in Medication and Outcomes
Maximizing the influence of RWD in cases of Rare Diseases Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	09:10 - 09:40
Population Adjusted RCTs – An Option for HTA Authorities Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company	09:40 - 10:10
Clinical Findings from Hospital Care Enriched by Unstructured Data Dries Hens, Chief Medical Officer, Co-founder , LynxCare Shahbaz Pervaiz, Director of RWE Services, LynxCare, Inc.	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking Meeting	10:45 - 11:30
Panel Discussion – Real-world Effectiveness- Does it Matter?’ Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company Christian Müller, Head of Data Generation, Bayer Ivan Clement, Global Associate Director, RWE & Innovative Evidence in Neuroscience , Novartis	11:30 - 12:05
Accelerate and de-risk Clinical Development & Market Access through AI-powered Real- World Disease and Care simulation. Alexandre Templier, Co-founder and President, Quinten Health	12:05 - 12:40
Let the Data Flow – Automated Digital Data Transfer from EHRs to EDC Christian Müller, Head of Data Generation, Bayer	12:40 - 13:15
Lunch \| One-to-One Networking	13:15 - 14:15
Spare a thought for the Hospitals – ‘The 3 Ps’ rule.\| One-to-One Networking Davy Yeung, Managing Director and Vice President of Operations, Tailored Clinical Research Solutions (TCRS)	14:15 - 14:50
From Data to Dialogue: Elevating Science-Based Communication in Post-Approval Studies Veronika Schweighart, Co-Founder, Climedo	14:50 - 15:20
RWE in Radiology: Promises and Pitfalls Oisin Butler, Integrated Evidence Generation Lead, Bayer Radiology	15:25 - 15:55
Evening Refreshments and Poster Presentation \| One-to-One Networking	15:55 - 16:45
Use of Real Word Data for Regulatory Decision Making Meritxell Sabido, Director- Global Epidemiology Department, Neurology and Immunology, Merck Healthcare KgaA	16:45 - 17:30
Closing remarks by the Chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	17:30 - 17:30
Drinks Reception and Networking	17:30 - 17:30
End of Day 1	17:30 - 17:30

Registration	08:15 - 09:00
Welcome note by MarketsandMarkets	09:00 - 09:05
Opening remarks by the Chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	09:05 - 09:10
Role of Real-World Evidence (RWE) in Market Access – Approach and Planning
Patient Centricity in Health Technology Assessment Remon Helmy, Associate Director, Health Economics & Outcomes Research (HEOR), Alexion, AstraZeneca Rare Disease	09:10 - 09:40
RWE in HTA- What does it mean in the ‘Real World’. Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB	09:40 - 10:10
Generating the Most Realistic Tailored Real World Evidence Possible Alberto Brage, Global Key Account Manager, Savanamed	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking	10:45 - 11:30
Panel Discussion - The Evolution of Registries and their Value for Patients’ Communities, Payers, and Regulators Anila Dede, Executive Director -Medical Affairs, RW Solutions, SyneosHealth Sandeep Kiri, Global Head of Health Economic Evidence- PPRWE, UCB Veronika Schweighart, Co-Founder, Climedo Remon Helmy, Associate Director, Health Economics & Outcomes Research (HEOR), Alexion, AstraZeneca Rare Disease	11:30 - 12:10
Creative use of RWD: How to Unlock the Potential of Data in Healthcare - Presentation of 2 cases study. Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	12:10 - 12:40
State-of-the-art statistical methods for modern HTA (Virtual /Pre-recorded) Michael Crowther, Founder and CEO, Red Door Analytics AB	12:40 - 13:10
Closing remarks by the chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	13:10 - 13:15
Lunch and Poster Presentation \| One-to-One Networking	13:15 - 13:15
End of Conference	13:15 - 13:15